Printer Friendly

VESTAR'S AMBISOME GAINS MARKETING AND REIMBURSEMENT APPROVAL IN SWEDEN

 VESTAR'S AMBISOME GAINS MARKETING
 AND REIMBURSEMENT APPROVAL IN SWEDEN
 SAN DIMAS, Calif., Jan. 15 /PRNewswire/ -- Vestar Inc. (NASDAQ: VSTR) today announced that AmBisome, the company's liposomal formulation of amphotericin B, has received full marketing approval by the Swedish Board of Health in Sweden, as a treatment for serious fungal infections. AmBisome also received reimbursement approval at a pricing level of 1,330 Swedish Krona, or approximately $230 per vial. The company will begin the commercial launch of the product immediately.
 "This very expeditious approval reflects the combined efforts of the Swedish Board of Health, as well as Vestar's exclusive pharmaceutical distributor for the Nordic countries, Swedish Orphan AB, and the company, to provide Swedish patients with advanced pharmaceuticals on a timely basis. We are extremely gratified by the rigorous scientific review that AmBisome has undergone successfully, and by the fairness of the reimbursement level," said Roger J. Crossley, M.D., president and chief executive officer of Vestar.
 AmBisome is now being sold in a total of 16 European countries, including the United Kingdom, either with full marketing approval or on a named-patient (compassionate) basis. Vestar believes that AmBisome is the only injectable liposomal pharmaceutical product to be approved in the Western Hemisphere.
 AmBisome is the company's trade name for its proprietary intravenous liposomal formulation of amphotericin B, the most commonly used drug for severe systemic fungal infections. The use of amphotericin B has been severely limited by its serious toxicity at doses that are only marginally effective. In contrast, AmBisome is well tolerated, permitting higher daily and cumulative doses than are considered safe for the conventional drug.
 Systemic fungal infections are serious infections with a mortality rate of up to 70 percent, that often occur in cancer patients treated with chemotherapy, particularly those with leukemia, as well as organ and bone marrow transplant patients, and AIDS patients.
 Vestar, headquartered in San Dimas, develops, manufactures and markets pharmaceuticals to treat patients with cancer and serious infections, including AIDS. The company's initial products use liposomes -- microscopic spheres with walls similar to those of cell membranes -- to encapsulate pharmaceuticals. Since 1989, Vestar has been marketing in Europe its first product, AmBisome, to treat systemic fungal infections. DaunoXome, a liposomal formulation of the chemotherapeutic agent daunorubicin, is in development as Vestar's second major product.
 -0- 1/15/92
 /CONTACT: Michael E. Hart, CFO of Vestar Inc., 714-394-4119; or Marcia A. Kean, executive VP of Feinstein Partners Inc., 617-577-8110, for Vestar Inc./
 (VSTR) CO: Vestar Inc. ST: California IN: MTC SU:


DM-JL -- LA007 -- 9941 01/15/92 11:03 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 1992
Words:425
Previous Article:COCA-COLA NESTLE VENTURE LAUNCHES FIRST BEVERAGE IN UNITED STATES (Product Announcement)
Next Article:BUSINESS TAX RETURNS DUE JAN. 31
Topics:


Related Articles
VESTAR'S DAUNOXOME (TM) PHASE I/II DATA PRESENTED AT ASH MEETING
POTENTIAL NEW TREATMENT FOR LEISHMANIASIS TO ENTER HUMAN CLINICAL TRIALS
VESTAR'S AMBISOME(R) GAINS MARKETING APPROVAL IN GERMANY
VESTAR, INC. REPORTS DAUNOXOME NOW AVAILABLE ON NAMED-PATIENT BASIS IN EUROPE
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN PORTUGAL
DATA ON NEW TREATMENT FOR VISCERAL LEISHMANIASIS PRESENTED AT THE XIII INTERNATIONAL CONGRESS FOR TROPICAL MEDICINE AND MALARIA
VESTAR'S DAUNOXOME DESIGNATED ORPHAN DRUG FOR KAPOSI'S SARCOMA
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN THE NETHERLANDS
VESTAR'S AMBISOME GAINS FULL MARKETING APPROVAL IN GREECE
VESTAR FILES AMENDED NDA FOR DAUNOXOME

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters